Cargando…
Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial
BACKGROUND: Prehypertension is associated with higher cardiovascular risk, target organ damage, and incidence of hypertension. The Prevention of Hypertension in Patients with PreHypertension (PREVER‐Prevention) trial aimed to evaluate the efficacy and safety of a low‐dose diuretic for the prevention...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210423/ https://www.ncbi.nlm.nih.gov/pubmed/27965209 http://dx.doi.org/10.1161/JAHA.116.004248 |
_version_ | 1782490884150919168 |
---|---|
author | Fuchs, Sandra Costa Poli‐de‐Figueiredo, Carlos E. Figueiredo Neto, José A. Scala, Luiz César N. Whelton, Paul K. Mosele, Francisca de Mello, Renato Bandeira Vilela‐Martin, José F. Moreira, Leila B. Chaves, Hilton Mota Gomes, Marco de Sousa, Marcos R. Silva, Ricardo Pereira e Castro, Iran Cesarino, Evandro José Jardim, Paulo Cesar Alves, João Guilherme Steffens, André Avelino Brandão, Andréa Araujo Consolim‐Colombo, Fernanda M. de Alencastro, Paulo Ricardo Neto, Abrahão Afiune Nóbrega, Antônio C. Franco, Roberto Silva Sobral Filho, Dario C. Bordignon, Alexandro Nobre, Fernando Schlatter, Rosane Gus, Miguel Fuchs, Felipe C. Berwanger, Otávio Fuchs, Flávio D. |
author_facet | Fuchs, Sandra Costa Poli‐de‐Figueiredo, Carlos E. Figueiredo Neto, José A. Scala, Luiz César N. Whelton, Paul K. Mosele, Francisca de Mello, Renato Bandeira Vilela‐Martin, José F. Moreira, Leila B. Chaves, Hilton Mota Gomes, Marco de Sousa, Marcos R. Silva, Ricardo Pereira e Castro, Iran Cesarino, Evandro José Jardim, Paulo Cesar Alves, João Guilherme Steffens, André Avelino Brandão, Andréa Araujo Consolim‐Colombo, Fernanda M. de Alencastro, Paulo Ricardo Neto, Abrahão Afiune Nóbrega, Antônio C. Franco, Roberto Silva Sobral Filho, Dario C. Bordignon, Alexandro Nobre, Fernando Schlatter, Rosane Gus, Miguel Fuchs, Felipe C. Berwanger, Otávio Fuchs, Flávio D. |
author_sort | Fuchs, Sandra Costa |
collection | PubMed |
description | BACKGROUND: Prehypertension is associated with higher cardiovascular risk, target organ damage, and incidence of hypertension. The Prevention of Hypertension in Patients with PreHypertension (PREVER‐Prevention) trial aimed to evaluate the efficacy and safety of a low‐dose diuretic for the prevention of hypertension and end‐organ damage. METHODS AND RESULTS: This randomized, parallel, double‐blind, placebo‐controlled trial was conducted in 21 Brazilian academic medical centers. Participants with prehypertension who were aged 30 to 70 years and who did not reach optimal blood pressure after 3 months of lifestyle intervention were randomized to a chlorthalidone/amiloride combination pill or placebo and were evaluated every 3 months during 18 months of treatment. The primary outcome was incidence of hypertension. Development or worsening of microalbuminuria, new‐onset diabetes mellitus, and reduction of left ventricular mass were secondary outcomes. Participant characteristics were evenly distributed by trial arms. The incidence of hypertension was significantly lower in 372 study participants allocated to diuretics compared with 358 allocated to placebo (hazard ratio 0.56, 95% CI 0.38–0.82), resulting in a cumulative incidence of 11.7% in the diuretic arm versus 19.5% in the placebo arm (P=0.004). Adverse events; levels of blood glucose, glycosylated hemoglobin, creatinine, and microalbuminuria; and incidence of diabetes mellitus were no different between the 2 arms. Left ventricular mass assessed through Sokolow‐Lyon voltage and voltage‐duration product decreased to a greater extent in participants allocated to diuretic therapy compared with placebo (P=0.02). CONCLUSIONS: A combination of low‐dose chlorthalidone and amiloride effectively reduces the risk of incident hypertension and beneficially affects left ventricular mass in patients with prehypertension. CLINICAL TRIAL REGISTRATION: URL: http://www.ClinicalTrials.gov, www.ensaiosclinicos.gov. Unique identifiers: NCT00970931, RBR‐74rr6s. |
format | Online Article Text |
id | pubmed-5210423 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-52104232017-01-05 Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial Fuchs, Sandra Costa Poli‐de‐Figueiredo, Carlos E. Figueiredo Neto, José A. Scala, Luiz César N. Whelton, Paul K. Mosele, Francisca de Mello, Renato Bandeira Vilela‐Martin, José F. Moreira, Leila B. Chaves, Hilton Mota Gomes, Marco de Sousa, Marcos R. Silva, Ricardo Pereira e Castro, Iran Cesarino, Evandro José Jardim, Paulo Cesar Alves, João Guilherme Steffens, André Avelino Brandão, Andréa Araujo Consolim‐Colombo, Fernanda M. de Alencastro, Paulo Ricardo Neto, Abrahão Afiune Nóbrega, Antônio C. Franco, Roberto Silva Sobral Filho, Dario C. Bordignon, Alexandro Nobre, Fernando Schlatter, Rosane Gus, Miguel Fuchs, Felipe C. Berwanger, Otávio Fuchs, Flávio D. J Am Heart Assoc Original Research BACKGROUND: Prehypertension is associated with higher cardiovascular risk, target organ damage, and incidence of hypertension. The Prevention of Hypertension in Patients with PreHypertension (PREVER‐Prevention) trial aimed to evaluate the efficacy and safety of a low‐dose diuretic for the prevention of hypertension and end‐organ damage. METHODS AND RESULTS: This randomized, parallel, double‐blind, placebo‐controlled trial was conducted in 21 Brazilian academic medical centers. Participants with prehypertension who were aged 30 to 70 years and who did not reach optimal blood pressure after 3 months of lifestyle intervention were randomized to a chlorthalidone/amiloride combination pill or placebo and were evaluated every 3 months during 18 months of treatment. The primary outcome was incidence of hypertension. Development or worsening of microalbuminuria, new‐onset diabetes mellitus, and reduction of left ventricular mass were secondary outcomes. Participant characteristics were evenly distributed by trial arms. The incidence of hypertension was significantly lower in 372 study participants allocated to diuretics compared with 358 allocated to placebo (hazard ratio 0.56, 95% CI 0.38–0.82), resulting in a cumulative incidence of 11.7% in the diuretic arm versus 19.5% in the placebo arm (P=0.004). Adverse events; levels of blood glucose, glycosylated hemoglobin, creatinine, and microalbuminuria; and incidence of diabetes mellitus were no different between the 2 arms. Left ventricular mass assessed through Sokolow‐Lyon voltage and voltage‐duration product decreased to a greater extent in participants allocated to diuretic therapy compared with placebo (P=0.02). CONCLUSIONS: A combination of low‐dose chlorthalidone and amiloride effectively reduces the risk of incident hypertension and beneficially affects left ventricular mass in patients with prehypertension. CLINICAL TRIAL REGISTRATION: URL: http://www.ClinicalTrials.gov, www.ensaiosclinicos.gov. Unique identifiers: NCT00970931, RBR‐74rr6s. John Wiley and Sons Inc. 2016-12-13 /pmc/articles/PMC5210423/ /pubmed/27965209 http://dx.doi.org/10.1161/JAHA.116.004248 Text en © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Fuchs, Sandra Costa Poli‐de‐Figueiredo, Carlos E. Figueiredo Neto, José A. Scala, Luiz César N. Whelton, Paul K. Mosele, Francisca de Mello, Renato Bandeira Vilela‐Martin, José F. Moreira, Leila B. Chaves, Hilton Mota Gomes, Marco de Sousa, Marcos R. Silva, Ricardo Pereira e Castro, Iran Cesarino, Evandro José Jardim, Paulo Cesar Alves, João Guilherme Steffens, André Avelino Brandão, Andréa Araujo Consolim‐Colombo, Fernanda M. de Alencastro, Paulo Ricardo Neto, Abrahão Afiune Nóbrega, Antônio C. Franco, Roberto Silva Sobral Filho, Dario C. Bordignon, Alexandro Nobre, Fernando Schlatter, Rosane Gus, Miguel Fuchs, Felipe C. Berwanger, Otávio Fuchs, Flávio D. Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial |
title | Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial |
title_full | Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial |
title_fullStr | Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial |
title_full_unstemmed | Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial |
title_short | Effectiveness of Chlorthalidone Plus Amiloride for the Prevention of Hypertension: The PREVER‐Prevention Randomized Clinical Trial |
title_sort | effectiveness of chlorthalidone plus amiloride for the prevention of hypertension: the prever‐prevention randomized clinical trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5210423/ https://www.ncbi.nlm.nih.gov/pubmed/27965209 http://dx.doi.org/10.1161/JAHA.116.004248 |
work_keys_str_mv | AT fuchssandracosta effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT polidefigueiredocarlose effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT figueiredonetojosea effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT scalaluizcesarn effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT wheltonpaulk effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT moselefrancisca effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT demellorenatobandeira effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT vilelamartinjosef effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT moreiraleilab effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT chaveshilton effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT motagomesmarco effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT desousamarcosr effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT silvaricardopereirae effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT castroiran effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT cesarinoevandrojose effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT jardimpaulocesar effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT alvesjoaoguilherme effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT steffensandreavelino effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT brandaoandreaaraujo effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT consolimcolombofernandam effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT dealencastropauloricardo effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT netoabrahaoafiune effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT nobregaantonioc effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT francorobertosilva effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT sobralfilhodarioc effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT bordignonalexandro effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT nobrefernando effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT schlatterrosane effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT gusmiguel effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT fuchsfelipec effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT berwangerotavio effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial AT fuchsflaviod effectivenessofchlorthalidoneplusamilorideforthepreventionofhypertensionthepreverpreventionrandomizedclinicaltrial |